See more : Technology One Limited (THNOF) Income Statement Analysis – Financial Results
Complete financial analysis of ProQR Therapeutics N.V. (PRQR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProQR Therapeutics N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- HUB Cyber Security (Israel) Ltd. (HUBC) Income Statement Analysis – Financial Results
- Urban Outfitters, Inc. (URBN) Income Statement Analysis – Financial Results
- C&G Systems Inc. (6633.T) Income Statement Analysis – Financial Results
- DFDS A/S (DFDS.CO) Income Statement Analysis – Financial Results
- Frasers Property Limited (FSRPF) Income Statement Analysis – Financial Results
ProQR Therapeutics N.V. (PRQR)
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 4.04M | 1.35M | 0.00 | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313.00K | 0.00 |
| Cost of Revenue | 133.52K | 2.48M | 0.00 | 2.19M | 116.82M | 983.51K | 1.00M | 1.28M | 482.85K | 0.00 | 0.00 |
| Gross Profit | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | 3.96M | -2.53M | 1.00M | 8.92M | 313.00K | 0.00 |
| Gross Profit Ratio | 97.95% | 38.68% | 100.00% | 0.00% | -5,943.61% | 80.09% | 165.49% | 43.84% | 94.87% | 100.00% | 0.00% |
| Research & Development | 25.15M | 50.87M | 42.22M | 38.14M | 46.49M | 29.51M | 31.15M | 31.92M | 23.40M | 10.27M | 2.57M |
| General & Administrative | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Other Expenses | -3.01M | -765.00K | -1.04M | 9.37M | 1.93M | 5.76M | 1.50M | 1.83M | 3.24M | 313.00K | 0.00 |
| Operating Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Cost & Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Interest Income | 2.59M | 106.00K | 5.00K | 313.00K | 402.00K | -792.00K | -3.18M | 470.00K | 6.17M | 4.33M | 24.00K |
| Interest Expense | 1.20M | 5.13M | 3.41M | 2.04M | 1.08M | 810.00K | 596.00K | 538.00K | 395.00K | 265.00K | 38.00K |
| Depreciation & Amortization | 2.51M | 2.48M | 2.42M | 2.19M | 2.05M | 983.51K | 1.00M | 1.28M | 480.00K | 126.00K | 24.00K |
| EBITDA | -24.10M | -56.46M | -54.95M | -136.56M | -174.27M | -35.29M | 0.00 | -120.55M | -84.24M | -49.70M | -3.19M |
| EBITDA Ratio | -369.93% | -1,470.99% | -4,089.81% | 0.00% | -2,965.65% | -831.05% | 2,676.78% | -1,759.68% | -316.34% | -5,318.85% | 0.00% |
| Operating Income | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | -36.29M | -40.50M | -39.57M | -27.00M | -16.46M | -3.24M |
| Operating Income Ratio | -489.09% | -1,603.07% | -4,223.86% | 0.00% | -2,971.81% | -734.53% | 2,648.66% | -1,734.14% | -287.05% | -5,259.11% | 0.00% |
| Total Other Income/Expenses | 4.05M | 1.05M | -3.47M | -4.12M | 117.65M | -792.00K | 850.31K | 470.00K | 6.17M | 4.33M | -14.00K |
| Income Before Tax | -27.81M | -64.80M | -61.56M | -46.49M | -56.61M | -37.09M | -43.67M | -39.10M | -20.83M | -12.13M | -3.25M |
| Income Before Tax Ratio | -426.97% | -1,605.03% | -4,546.75% | 0.00% | -2,928.82% | -750.56% | 2,856.31% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| Income Tax Expense | -78.00K | 96.00K | 117.00K | 124.00K | 132.00K | 1.00K | 2.00K | -470.00K | -6.17M | -4.33M | 24.00K |
| Net Income | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M | -36.89M | -43.64M | -39.10M | -20.83M | -12.13M | -3.25M |
| Net Income Ratio | -431.67% | -1,607.41% | -4,555.39% | 0.00% | -2,935.64% | -746.69% | 2,853.96% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| EPS | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS Diluted | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| Weighted Avg Shares Out | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| Weighted Avg Shares Out (Dil) | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
ProQR Announces Third Quarter 2020 Operating and Financial Results
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
Source: https://incomestatements.info
Category: Stock Reports